Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04212351 · ClinicalTrials.gov registry record
Frameshift Peptides of Children With NF1
A clinical trial, sponsored by Children's National Research Institute.
- Completed
- Registry status
- 60
- Enrollment target
NCT04212351 is a clinical trial that has completed, run by Children's National Research Institute. The registered enrollment target is 60 participants.
The verdict
NCT04212351 has completed, sponsored by Children's National Research Institute.
- COMPLETED
- Registry status
- 60 participants
- Enrollment target
Study Summary
The objective of this study is to determine if children and young adults with Neurofibromatosis Type 1 (NF1) and either Low Grade Gliomas (LGGs) or Plexiform Neurofibromas (PNs) have a specific frameshift peptide protein profile and whether a disease specific vaccine created to address these frameshift mutations and variants can be developed. Three study populations will be analyzed; patients with NF1 and active LGGs, NF1 and active PNs, and NF1 and no evidence of active LGGs or PNs. Participation involves a onetime blood draw.
Interventions
- GENETIC Frameshift Array blood sample test
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2019-04-11 |
| Est. Completion | 2022-04-27 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04212351
The ClinicalTrials.gov registry entry for NCT04212351 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's National Research Institute, which has 92 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Frameshift Array blood sample test is the first listed.
NCT04212351 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04212351 about?
NCT04212351 is a clinical study titled "Frameshift Peptides of Children With NF1". The objective of this study is to determine if children and young adults with Neurofibromatosis Type 1 (NF1) and either Low Grade Gliomas (LGGs) or Plexiform Neurofibromas (PNs) have a specific frameshift peptide protein profile and whether a disease specific vaccine created to address these framesh...
What is the current status of trial NCT04212351?
This trial is currently completed. The enrollment target is 60 participants. The study started on 2019-04-11. Estimated completion is 2022-04-27.
What interventions are being tested in trial NCT04212351?
The interventions under investigation include: Frameshift Array blood sample test (GENETIC).
Who is sponsoring clinical trial NCT04212351?
This trial is sponsored by Children's National Research Institute, which has 92 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.